Cogent Biosciences, Inc. (COGT)

NASDAQ: COGT · Real-Time Price · USD
7.60
-0.24 (-3.06%)
Dec 23, 2024, 10:49 AM EST - Market open
-3.06%
Market Cap 839.51M
Revenue (ttm) n/a
Net Income (ttm) -242.30M
Shares Out 110.46M
EPS (ttm) -2.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 210,738
Open 7.81
Previous Close 7.84
Day's Range 7.45 - 7.90
52-Week Range 4.28 - 12.61
Beta -0.05
Analysts Buy
Price Target 14.20 (+86.84%)
Earnings Date Nov 12, 2024

About COGT

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 29, 2018
Employees 164
Stock Exchange NASDAQ
Ticker Symbol COGT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for COGT stock is "Buy." The 12-month stock price forecast is $14.2, which is an increase of 86.84% from the latest price.

Price Target
$14.2
(86.84% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Is Cogent Biosciences Stock Trading Higher On Monday?

On Sunday, Cogent Biosciences, Inc.  COGT revealed updated clinical results from the Open Label Extension (OLE) portion of the SUMMIT trial of bezuclastinib in patients with non-advanced systemic mast...

13 days ago - Benzinga

Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients

56% mean improvement in Total Symptom Score (TSS) at 24 weeks with 76% of patients achieving at least a 50% reduction in TSS

14 days ago - GlobeNewsWire

Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID 88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID Median time to response 2.2 months with me...

14 days ago - GlobeNewsWire

Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions

6 months ago - GlobeNewsWire

Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

7 months ago - GlobeNewsWire

Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting

WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

7 months ago - GlobeNewsWire

Cogent Biosciences Reports First Quarter 2024 Financial Results

SUMMIT, PEAK and APEX registration-directed clinical trial enrollment remains on track; topline results expected from all three studies in 2025

8 months ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

•   UMMIT Part 2 registration-directed study of bezuclastinib in NonAdvSM patients initiated and actively enrolling at 40 sites globally; once-daily 100 mg selected as RP2D; topline results expected b...

10 months ago - GlobeNewsWire

Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis

Registration-enabling SUMMIT Part 2 initiated and actively enrolling at 40 sites globally; RP2D selected at 100 mg once-daily optimized formulation based on:

10 months ago - GlobeNewsWire

Cogent Biosciences Announces Oversubscribed $225 Million Private Placement

Pro-forma cash, cash equivalents and marketable securities expected to fund the Company into 2027 and through clinical readouts from ongoing SUMMIT, PEAK and APEX registration-directed trials

11 months ago - GlobeNewsWire

Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting

Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET Company to Host Virtual Investor Webcast on Friday, February 23 at 8:00 a.m. ET

11 months ago - GlobeNewsWire

Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics

WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc.  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

1 year ago - GlobeNewsWire

Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass. and BOULDER, Colo., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

1 year ago - GlobeNewsWire

Cogent Biosciences stock drops as analysts see tough competition for mastocytosis treatment

Cogent Biosciences Inc. shares COGT, -1.48% fell more than 30% premarket on Monday after the company over the weekend released clinical trial data on its lead drug candidate that failed to outshine po...

1 year ago - Market Watch

Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

56% ORR in TKI-naïve patients, including 86% ORR by PPR criteria and 100% ORR in APEX patients treated at 100 mg BID with exposures consistent with go-forward dose

1 year ago - GlobeNewsWire

Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)

Rapid and ongoing improvement in patient symptoms, with 57% median best improvement on MC-QoL and 78% of patients reporting ≥1 point improvement on PGIS by week 20

1 year ago - GlobeNewsWire

Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3Kα inhibitor programs at the San Antonio Breast Cancer Symposium

Novel EGFR-sparing, brain-penetrant ErbB2 inhibitor demonstrates superior efficacy profile reaching 80% brain penetrance with potent coverage of key mutations inadequately addressed by currently appro...

1 year ago - GlobeNewsWire

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium

WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

1 year ago - GlobeNewsWire

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results

SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation

1 year ago - GlobeNewsWire

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches –

1 year ago - GlobeNewsWire

Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor

Cogent Biosciences, Inc. is developing the lead asset bezuclastinib, a KIT inhibitor, in various indications. The company has demonstrated positive clinical data for bezuclastinib in advanced systemic...

1 year ago - Seeking Alpha

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results

Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023

1 year ago - GlobeNewsWire

3 Lost Formula Stocks to Consider for the 2nd Half of 2023

Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

Other symbols: CRCIRWD
1 year ago - GuruFocus

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock

WALTHAM, Mass. and BOULDER, Colo., June 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

1 year ago - GlobeNewsWire